Medizintechnologie e.V.
Reinhardtstr. 29 b
D - 10117 Berlin
Tel. (030) 246 255 - 0
Fax. (030) 246 255 - 99
info@bvmed.de
BVMed
BVMed Annual Report 2000/01: Innovative medical technologies will remain high on the agenda - Industry wants more rights in health technology assessment and DRG implementation
BVMed will continue to point out the importance of timely patient access to innovative medical technologies and will put the attention on restraints to this goal. The restraints range from increasing "criminalization" of the necessary sponsoring of medical research in hospitals, all the way to slow and intransparent health technology assessment procedures. Joachim M. Schmitt: "Timely patient access to new medical therapies, procedures and technologies is an essential part of high-quality provision of health care for the patients."
It is stated in BVMed's annual report that when developing and introducing the new reimbursement system in the hospital (G-DRG System – German Diagnosis Related Groups), industry should be involved from the beginning by accompanying and co-consulting the proceedings. A further focal point is Health Technology Assessment (HTA). The two committees "Federal Standing Committee of Physicians and Sickness Funds" (Bundesausschuss Ärzte - Krankenkassen) and "Federal Hospital Committee" (Bundesausschuss Krankenhaus) decide on the introduction of new medical technologies. However, the decision structures are nontransparent and too slow. Therefore, BVMed demands more efficient and more transparent decisions. "Industry has to be involved more in the procedures. The simple right to attend qualified hearings is not enough. Industry needs the right of initiative and participation", BVMed emphasized.
The just published 24-page Annual Report 2000/01 addresses the overall development of the medical technology industry as well as the issues of the specific working areas "health policy", "medical device legislation", "consumer protection" and "communication/press".




